<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421691</url>
  </required_header>
  <id_info>
    <org_study_id>C-16-EV10</org_study_id>
    <nct_id>NCT03421691</nct_id>
  </id_info>
  <brief_title>A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation</brief_title>
  <official_title>A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to evaluate the safety and efficacy of the Cutera excel&#xD;
      V Laser Genesis procedure utilizing the 1064nm Nd:YAG laser for skin rejuvenation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center prospective, open-label uncontrolled study in 15 male or female&#xD;
      subjects, age 35 to 55 years who desire non-ablative laser treatment for facial&#xD;
      photo-rejuvenation, specifically improvement of rhytides, lentigines, erythema,&#xD;
      telangiectasia and skin texture. Subjects will receive up to 6 laser treatments spaced 2 to 4&#xD;
      weeks apart and complete two follow-up visits; one at 4 weeks and one at 12 weeks post-final&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 15, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of Improvement Rating #1</measure>
    <time_frame>4 week post-final treatment and 12 weeks post-final treatment</time_frame>
    <description>Rate the degree of improvement from Baseline observed in the post-treatment photographs (4 weeks and 12 weeks) as assessed by independent blinded Reviewers using the Physician's Global Assessment of Improvement Scale (GAIS) GAIS: +4=Very Significant Improvement (&gt; 75%),+3=Significant Improvement(51 - 75%), +2=Moderate Improvement(26 - 50%), +1=Mild Improvement(5 - 25%) and 0=No Change(&lt;5%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Improvement Rating #2</measure>
    <time_frame>4 week post-final treatment and 12 weeks post-final treatment</time_frame>
    <description>Rate the degree of improvement from Baseline observed in the post-treatment photographs (4 weeks and 12 weeks) as assessed by the Investigator using the Physician's Global Assessment of Improvement Scale (GAIS) GAIS: +4=Very Significant Improvement (&gt; 75%),+3=Significant Improvement(51 - 75%), +2=Moderate Improvement(26 - 50%), +1=Mild Improvement(5 - 25%) and 0=No Change(&lt;5%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Improvement Rating #3</measure>
    <time_frame>4 week post-final treatment and 12 weeks post-final treatment</time_frame>
    <description>Rate the degree of improvement from Baseline observed in the post-treatment photographs (4 weeks and 12 weeks) as assessed by the Subject using the Physician's Global Assessment of Improvement Scale (GAIS) GAIS: +4=Very Significant Improvement (&gt; 75%),+3=Significant Improvement(51 - 75%), +2=Moderate Improvement(26 - 50%), +1=Mild Improvement(5 - 25%) and 0=No Change(&lt;5%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness Assessment: Temporal Order</measure>
    <time_frame>12 weeks post-final treatment</time_frame>
    <description>Correct identification of the temporal order of each photograph pair (Baseline, 4 weeks post-treatment, 12 weeks post-treatment) as determined by independent blinded reviewers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Skin Pigment</condition>
  <condition>Photoaging</condition>
  <arm_group>
    <arm_group_label>Excel V laser</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>excel V Laser</intervention_name>
    <description>excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser</description>
    <arm_group_label>Excel V laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or Male, 35 to 55 years of age (inclusive).&#xD;
&#xD;
          2. Fitzpatrick Skin Type I - IV (Appendix 4).&#xD;
&#xD;
          3. Desires non-invasive and non-ablative treatment of skin-aging or photo-rejuvenation of&#xD;
             the skin.&#xD;
&#xD;
          4. Have signs of moderate skin aging, including presence of mild to moderate rhytides&#xD;
             around eyes and upper lip, multiple lentigines, diffuse erythema or telangiectasia,&#xD;
             and a score between 4 and 7 (inclusive) on the Fitzpatrick Wrinkle Classification&#xD;
             Scale (Appendix 3).&#xD;
&#xD;
          5. Subject must be able to read, understand and sign the Informed Consent Form.&#xD;
&#xD;
          6. Must be willing and able to adhere to the treatment and follow-up schedule and&#xD;
             post-treatment care instructions.&#xD;
&#xD;
          7. Willing to have very limited sun exposure and use an approved sunscreen of SPF 30 or&#xD;
             higher on the treatment area every day for the duration of the study, including the&#xD;
             follow-up period.&#xD;
&#xD;
          8. Willing to have digital photographs taken of the treatment area and agree to use of&#xD;
             photographs for presentation, educational or marketing purposes.&#xD;
&#xD;
          9. Agree to not undergo any other procedure(s) for skin rejuvenation during the study,&#xD;
             including but not limited to chemical peel, laser and light based device treatment,&#xD;
             and home-use device treatment.&#xD;
&#xD;
         10. Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid&#xD;
             filler or other dermal filler during the study.&#xD;
&#xD;
         11. Post-menopausal or surgically sterilized, or using a medically acceptable form of&#xD;
             birth control at least 3 months prior to enrollment and during the entire course of&#xD;
             the study, and no plans to become pregnant or to father a child for the duration of&#xD;
             the study.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in a clinical trial of another device or drug within 6 months prior to&#xD;
             enrollment or during the study.&#xD;
&#xD;
          2. Any type of prior cosmetic treatment to the target area within 6 months of study&#xD;
             participation, such as laser or light-based procedures or surgery.&#xD;
&#xD;
          3. Prior injection to the face of botulinum toxin, collagen, hyaluronic acid filler or&#xD;
             other dermal filler within 6 months of study participation, as applicable.&#xD;
&#xD;
          4. Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable,&#xD;
             within 6 months of study participation.&#xD;
&#xD;
          5. Use of topical medications on the face, such as antibiotics, benzoyl peroxide,&#xD;
             retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing&#xD;
             dihydroxyacetone or alpha-hydroxy with concentration &gt; 8%, within 1 month of&#xD;
             participation.&#xD;
&#xD;
          6. History of malignant tumors in the target area.&#xD;
&#xD;
          7. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large&#xD;
             moles.&#xD;
&#xD;
          8. Pregnant and/or breastfeeding.&#xD;
&#xD;
          9. Having an infection, dermatitis or a rash in the treatment area.&#xD;
&#xD;
         10. Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,&#xD;
             e.g., uncontrolled hypertension.&#xD;
&#xD;
         11. Suffering from coagulation disorders, or taking prescription anticoagulation&#xD;
             medication which might make study participation unsafe according to Investigator's&#xD;
             discretion.&#xD;
&#xD;
         12. History of keloid scarring, hypertrophic scarring or of abnormal wound healing.&#xD;
&#xD;
         13. History of immunosuppression/immune deficiency disorders or currently using&#xD;
             immunosuppressive medications.&#xD;
&#xD;
         14. History of vitiligo, eczema, or psoriasis.&#xD;
&#xD;
         15. History of connective tissue disease, such as systemic lupus erythematosus or&#xD;
             scleroderma.&#xD;
&#xD;
         16. History of seizure disorders due to light.&#xD;
&#xD;
         17. Any use of medication that is known to increase sensitivity to light according to&#xD;
             Investigator's discretion.&#xD;
&#xD;
         18. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes&#xD;
             zoster (shingles) in the treatment area, unless treatment is conducted following a&#xD;
             prophylactic regimen.&#xD;
&#xD;
         19. History of radiation to the treatment area or undergoing systemic chemotherapy for the&#xD;
             treatment of cancer.&#xD;
&#xD;
         20. History of pigmentary disorders, particularly tendency for hyper- or&#xD;
             hypo-pigmentation.&#xD;
&#xD;
         21. Anytime in life, having have used gold therapy (gold salts) for disorders such as&#xD;
             rheumatologic disease or lupus.&#xD;
&#xD;
         22. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning&#xD;
             during the study.&#xD;
&#xD;
         23. Current smoker or history of smoking within 6 months of study participation.&#xD;
&#xD;
         24. As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michaela Bell</last_name>
    <phone>415-657-5722</phone>
    <email>mbell@cutera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Pocock</last_name>
    <phone>415-657-5702</phone>
    <email>gpocock@cutera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialists of NY and NJ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Bloom, MD</last_name>
      <email>drbloom@skinandlasers.com</email>
    </contact>
    <contact_backup>
      <last_name>Diana Aranzazu</last_name>
      <email>dianaa@skinandlasers.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pigmentation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

